Results 111 to 120 of about 607,470 (403)

Echocardiography-guided percutaneous intramyocardial alginate hydrogel implants for heart failure: canine models with 6-month outcomes

open access: yesFrontiers in Cardiovascular Medicine
BackgroundEchocardiography-guided percutaneous intramyocardial alginate-hydrogel implantation (PIMAHI) is a novel treatment approach for heart failure (HF).
Hui Ma   +8 more
doaj   +1 more source

Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy. [PDF]

open access: yes, 2015
Background: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder characterized by unexplained left ventricle hypertrophy associated with non-dilated ventricular chambers.
BOTTILLO, IRENE   +12 more
core   +1 more source

Reversible Cardiomyopathies

open access: yesClinical Medicine Insights: Cardiology, 2015
Cardiomyopathies (CMs) have many etiological factors that can result in severe structural and functional dysregulation. Fortunately, there are several potentially reversible CMs that are known to improve when the root etiological factor is addressed. In this article, we discuss several of these reversible CMs, including tachycardia-induced, peripartum,
Harsh Patel   +4 more
openaire   +4 more sources

Post‐Translational Modifications in Cilia and Ciliopathies

open access: yesAdvanced Science, EarlyView.
This review synthesizes current understanding of post‐translational modifications (PTMs) in ciliary proteins and emphasizes their roles in ciliary formation, homeostasis, and signaling. This review also discusses the implication of PTM dysregulation in ciliopathies and explores therapeutic strategies targeting PTM‐modifying enzymes.
Jie Ran, Jun Zhou
wiley   +1 more source

Cardiomyopathies in children [PDF]

open access: yesKorean Journal of Pediatrics, 2013
Cardiomyopathy (CMP) is a heterogeneous disease caused by a functional abnormality of the cardiac muscle. CMP is of 2 major types, dilated and hypertrophic, and is further classified as either primary or secondary. Secondary CMP is caused by extrinsic factors, including infection, ischemia, hypertension, and metabolic disorders.
openaire   +3 more sources

Irisin Attenuates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension via Ubiquitin‐Mediated Regulation of ENO1

open access: yesAdvanced Science, EarlyView.
Irisin is a crucial plasma biomarker and promising therapeutic target that reflects disease severity, pulmonary vascular remodeling status and clinical outcome in patients with pulmonary arterial hypertension (PAH). As a novel protective factor, irisin is downregulated in PAH. By ubiquitination, irisin promotes Enolase 1 degradation and suppresses cell
Na Sun   +15 more
wiley   +1 more source

Predictive value of estimated plasma volume for postoperative hypotension in percutaneous intramyocardial septal radiofrequency ablation treating for hypertrophic obstructive cardiomyopathy

open access: yesBMC Cardiovascular Disorders
Background Estimated plasma volume status (ePVS) estimated by the Duarte formula is associated with clinical outcomes in patients with heart failure.
Bo Shan   +8 more
doaj   +1 more source

Lactate‐Activated GPR132‐Src Signal Induces Macrophage Senescence and Aggravates Atherosclerosis Under Diabetes

open access: yesAdvanced Science, EarlyView.
Elevated lactate in diabetes activates the GPR132‐Src pathway in macrophages, inducing macrophage senescence and further enhancing foam cell formation. This mechanism exacerbates atherosclerotic progression. Abstract Diabetes is widely acknowledged as a significant risk factor for atherosclerosis, facilitating plaque formation through various ...
Xiaofeng Ge   +10 more
wiley   +1 more source

Peripartum cardiomyopathy: an update [PDF]

open access: yes, 1991
Purpose of Review Peripartum cardiomyopathy (PPCM) is an idiopathic disorder defined as heart failure occurring in women during the last month of pregnancy and up to 5 months postpartum.
Azibani, Feriel, Sliwa-Hahnle, Karen
core   +6 more sources

Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. [PDF]

open access: yes, 2014
BACKGROUND: Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac structural changes before the development of left ventricular hypertrophy (LVH).
Bassett, P   +18 more
core   +1 more source

Home - About - Disclaimer - Privacy